BioCentury | Sep 26, 2018
Distillery Therapeutics

Neurology

...a patient-derived fibroblast cell line, an HDAC6 inhibitor tool compound or the HDAC inhibitor Zolinza vorinostat...
...of impaired autophagy markers compared with vehicle. In a Caenorhabditis elegans model of Cockayne syndrome, Zolinza...
...levels of impaired autophagy markers compared with vehicle. In a mouse model of the disease, Zolinza...
BioCentury | Aug 10, 2018
Clinical News

FDA approves Kyowa's Poteligeo for CTCL

...PFS) benefit over histone deacetylase (HDAC) inhibitor Zolinza vorinostat from Merck & Co. Inc. (NYSE:MRK). Zolinza...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...of the tool compound MDM2 inhibitor nutlin-3 linked to analogs of the HDAC inhibitor Zolinza vorinostat...
...50 of 0.91 μM and increased levels of markers of apoptosis compared with nutlin-3 or Zolinza...
...includes optimization of the compound. Merck & Co. Inc. and Taiho Pharmaceutical Co. Ltd. market Zolinza...
BioCentury | Aug 8, 2018
Company News

FDA approves Kyowa's Poteligeo for CTCL

...PFS) benefit over histone deacetylase (HDAC) inhibitor Zolinza vorinostat from Merck & Co. Inc. (NYSE:MRK). Zolinza...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Otologic

...the REST mutation resulted in hearing loss, and in these mice, the HDAC inhibitor Zolinza vorinostat...
...testing additional HDAC inhibitors in mouse models of hereditary deafness. Merck & Co. Inc. markets Zolinza...
...doi:10.1016/j.cell.2018.06.004 CONTACT: Botond Bánfi, University of Iowa, Iowa City, Iowa email: botond-banfi@uiowa.edu Sandi Wong Vorinostat MSD, Zolinza, vorinostat (Suberoylanilide hydroxamic acid (SAHA)) University...
BioCentury | Jun 29, 2018
Preclinical News

Inhibiting REST in hair cells to reduce hearing loss

...heterozygous REST knockout, indirect inhibition of REST activity through the administration of HDAC inhibitor Zolinza vorinostat...
...Co. Inc. (NYSE:MRK) markets Zolinza to treat cutaneous T cell lymphoma (CTCL). Sandi Wong Vorinostat MSD, Zolinza, vorinostat (Suberoylanilide hydroxamic acid (SAHA)) Merck...
BioCentury | Dec 15, 2017
Clinical News

Kyowa's Poteligeo meets in Phase III for CTCL

...endpoint, Poteligeo led to a median PFS of 7.7 months vs. 3.1 months for Zolinza vorinostat...
...active comparator. Poteligeo also met the secondary endpoint of improving overall response rate (ORR) vs. Zolinza...
...and then on days 1 and 15 of subsequent cycles, or once-daily 400 mg oral Zolinza...
BioCentury | Dec 10, 2017
Clinical News

Kyowa's Poteligeo meets in Phase III for CTCL

...endpoint, Poteligeo led to a median PFS of 7.7 months vs. 3.1 months for Zolinza vorinostat...
...active comparator. Poteligeo also met the secondary endpoint of improving overall response rate (ORR) vs. Zolinza...
...CD194). Zolinza is a histone deacetylase (HDAC) inhibitor from Merck & Co. Inc. (NYSE:MRK). Elizabeth S. Eaton mogamulizumab Poteligeo vorinostat Zolinza Kyowa...
BioCentury | Sep 20, 2017
Distillery Therapeutics

Cancer

...decreased tumor growth compared with a NamPRT inhibitor tool compound or the HDAC inhibitor Zolinza vorinostat...
...optimization of the dual inhibitor. Merck & Co. Inc. and Taiho Pharmaceutical Co. Ltd. market Zolinza...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Transplant

...transplant (HSCT). In a mouse model of HSCT-associated IPS, the pan-HDAC inhibitors pracinostat and Zolinza vorinostat...
...AML) and myelodysplastic syndrome (MDS). Merck & Co. Inc. and Taiho Pharmaceutical Co. Ltd. market Zolinza...
...2017 doi:10.1073/pnas.1615280114 CONTACT: Su-Kil Seo, Inje University College of Medicine, Busan, South Korea email: sseo@inje.ac.kr Claire Quang pracinostat vorinostat Inje...
Items per page:
1 - 10 of 146